Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;126(5):279-84.
doi: 10.1590/s1516-31802008000500007.

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

Virgínia Fernandes Moça Trevisani  1 , Rachel Riera, Aline Mizusaki Imoto, Humberto Saconato, Alvaro Nagib Atallah
Affiliations

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

Virgínia Fernandes Moça Trevisani et al. Sao Paulo Med J. 2008 Sep.

Abstract
in English, Portuguese

Context and objective: Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis.

Methods: A systematic review was conducted using the Cochrane Collaboration methodology.

Results: 1) Teriparatide 20 microg or 40 microg versus placebo: there was a benefit from teriparatide, considering the following outcomes: reduction in the number of new vertebral and non-vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density. 2) Teriparatide 40 microg versus alendronate 10 mg/day for 14 months: there was no statistical difference regarding the incidence of new vertebral or non-vertebral fractures, although in the group that received teriparatide there was greater bone mineral density increase in the whole body, lumbar column and femur. 3) Estrogen plus teriparatide 25 microg versus estrogen: there was a benefit, considering the following outcomes: reduction in the number of new vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density after three years.

Conclusions: When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures (67%) and non-vertebral fractures (38%) and increases bone mineral density in the lumbar column and femur. There is a need for studies with longer observation in order to allow conclusions regarding the safety and duration of the therapeutic effects.

CONTEXTO E OBJETIVO:: A osteoporose é definida como uma doença caracterizada por baixa massa óssea e deteriorização da microarquiquetura do tecido ósseo. O paratormônio estimula a formação e a ação dos osteoblastos responsáveis pela formação dos ossos, promovendo ganho de tecido ósseo. O objetivo foi determinar a efetividade e a segurança da teriparatida no tratamento da osteoporose pós-menopausa.

MÉTODOS:: Foi realizada uma revisão sistemática da literatura de acordo com a metodologia da Colaboração Cochrane.

RESULTADOS:: 1) Teriparatida 20 µg ou 40 µg versus placebo: benefício da teriparatida considerando os desfechos redução do número de novas fraturas vertebrais e não-vertebrais, aumento da densidade mineral óssea corporal total, lombar e do fêmur. 2) Teriparatida 40 µg versus alendronato 10 mg/dia por 14 meses: não houve diferença estatística em relação a incidência de novas fraturas vertebrais ou não-vertebrais, porém, no grupo que recebeu a teriparatida, houve maior ganho de densidade mineral óssea corporal total, na coluna lombar e no fêmur (região intertrocantérica e triângulo de Wards). 3) Estrogênio mais teriparatida 25 µg versus estrogênio: houve benefício do estrogênio associado a teriparatida considerando os desfechos redução do número de novas fraturas vertebrais, aumento da densidade mineral óssea corporal total, lombar e do fêmur ao final dos três anos do estudo.

CONCLUSÕES:: A teriparatida, quando administrada em baixas doses e de forma intermitente, reduz as fraturas vertebrais (67%) e não vertebrais (38%) e aumenta a densidade mineral óssea na coluna lombar e no fêmur. Há necessidade de estudos de maior tempo de observação para permitir conclusões sobre a segurança e a duração dos efeitos terapêuticos.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Not declared

Figures

Figure 1.
Figure 1.. Result from the systematic review
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Consensus development conference: prophylaxis and treatment of osteoporosis. Br Med J (Clin Res Ed) 1987;295(6603):914–915. - PMC - PubMed
    1. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–1141. - PubMed
    1. Doherty DA, Sanders KM, Kotowicz MA, Prince RL. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int. 2001;12(1):16–23. - PubMed
    1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–1936. - PubMed
    1. Cranney A, Simon LS, Tugwell P, Adachi R, Ottawa Methods Group . London: BMJ Books; 2003. Osteoporosis. In: Evidence-based Rheumatology; pp. 225–232. Available from http://www.blackwellpublishing.com/medicine/bmj/rheumatology/pdfs/alen.pdf. Accessed in 2008 (Sep 23)

Publication types

LinkOut - more resources